Ribosomal protein S6 is hyperactivated and differentially phosphorylated in epidermal lesions of patients with psoriasis and atopic dermatitis
Authors:
- 9 November 2014
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 171 (6) , 1533-1536
Abstract
The ribosomal protein S6 is part of the translation machinery and is activated by phosphorylation via the mammalian target of rapamycin pathway, which is activated in psoriatic skin. To investigate which S6 sites are phosphorylated in psoriasis and atopic dermatitis (AD), and to study whether S6 phosphorylation is associated with inflammation and/or keratinocyte hyperproliferation. Healthy skin and skin lesions of patients with psoriasis and AD were investigated by immunostaining using antibodies that stain proliferating cells, leucocytes and distinct phosphorylated sites of S6. All psoriasis and AD lesions revealed abnormal S6 phosphorylation in the epidermis. The extent of S6 phosphorylation was diverse, generally stronger in psoriasis and correlated, in both diseases, with inflammation. S6 showed differential phosphorylation in distinct epidermal layers, which was most pronounced in hyperproliferative regions. Differential S6 phosphorylation may have a role in abnormal keratinocyte proliferation/differentiation.Keywords
Funding Information
- UBS Optimus Foundation (no)
This publication has 15 references indexed in Scilit:
- Regulation of Ribosomal Protein S6 Phosphorylation by Casein Kinase 1 and Protein Phosphatase 1Journal of Biological Chemistry, 2011
- Insulin‐like growth factor‐1 in psoriatic plaques treated with PUVA and methotrexateJournal of the European Academy of Dermatology and Venereology, 2011
- Differential expression of phosphorylated extracellular signal‐regulated kinase 1/2, phosphorylated p38 mitogen‐activated protein kinase and nuclear factor‐κB p105/p50 in chronic inflammatory skin diseasesThe Journal of Dermatology, 2009
- RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent TranslationJournal of Biological Chemistry, 2007
- Severe psoriasis treated with a new macrolide: everolimusBritish Journal of Dermatology, 2006
- Insulin-Like Growth Factor 1 Receptor Signaling Regulates Skin Development and Inhibits Skin Keratinocyte DifferentiationMolecular and Cellular Biology, 2006
- Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trialBritish Journal of Dermatology, 2005
- The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skinBritish Journal of Dermatology, 2005
- Will mTOR inhibitors make it as cancer drugs?Cancer Cell, 2003
- Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinasesCell, 1992